<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011868</url>
  </required_header>
  <id_info>
    <org_study_id>1245.33</org_study_id>
    <secondary_id>2009-013668-38</secondary_id>
    <nct_id>NCT01011868</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of
      BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in
      combination with basal insulin in patients with type 2 diabetes mellitus with insufficient
      glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment</measure>
    <time_frame>Baseline and 18 weeks</time_frame>
    <description>Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline and 18, 54 and 78 weeks</time_frame>
    <description>Patients that had a reduction in HbA1c of at least 0.5% from baseline to 18, 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
    <description>Change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
    <description>Percent change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 54 and 78 weeks</time_frame>
    <description>Change from baseline in basal insulin dose/day after 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 18, 54, 78 weeks</time_frame>
    <description>Change from baseline in body weight after 18, 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Follow-up</measure>
    <time_frame>Baseline and 82 weeks</time_frame>
    <description>Change from baseline in body weight at follow up (82 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 54 and 78 weeks</time_frame>
    <description>Change from baseline in HbA1c after 54 and 78 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of &lt;7.0% After 18, 54, and 78 Weeks of Treatment</measure>
    <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
    <description>The occurrence of treat to target efficacy response, that is an HbA1c under treatment of &lt;7.0% After 18, 54, and 78 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycemic Events</measure>
    <time_frame>During the course of the study (82 weeks)</time_frame>
    <description>Confirmed hypoglycemic events refer to all hypoglycemic events that had a glucose value â‰¤70 ml/dL or where assistance was required. Symptomatic hypoglycemic events were to be reported as adverse events. Investigator-defined hypoglycaemia adverse events include all events that investigator marked as 'Hypoglycaemic event' in CRFs, regardless of the reported term or blood glucose value. It may include hypoglycemia itself as reported term or any other symptoms that that investigator may have attributed to hypoglycemia (e.g. dizziness, hyperhidrosis, and asthenia).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773 low dose daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773 high dose daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo to match BI 10773 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 placebo</intervention_name>
    <description>BI 10773 placebo</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose</intervention_name>
    <description>BI 10773 low dose</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 high dose</intervention_name>
    <description>BI 10773 high dose</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 placebo</intervention_name>
    <description>BI 10773 placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation

          2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a
             stable dose of basal insulin with or without concomitant metformin and / or
             sulfonylurea.

          3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of &gt;7.0% and &lt; or = 10% at Visit 1
             (screening)

          4. Suitability for trial participation according to investigator's judgment (evaluating
             all alternative treatment options and in consideration of the patient completing the
             study)

          5. Age &gt; or =18 years at Visit 1 (screening)

          6. BMI &lt; or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)

        Exclusion criteria:

          1. Patients with poorly controlled hyperglycemia

          2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on
             basal insulin therapy

          3. MI, stroke, or TIA within 3 months prior to obtaining informed consent

          4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years;
             blood dyscrasias

        6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid
        hormones, participation in another trial with an investigational drug 7. Pre-menopausal
        women on insufficient birth control 8. Alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.33.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradednton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hartford</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carlisle</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Landsdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>HillerÃ¸d</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>KÃ¸benhavn NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montbrison</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanterre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint MandÃ©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dorking</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Headington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wembley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.33.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wymondham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>September 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2014</results_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral Placebo</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg orally once daily</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>After Week 18 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Week 78 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) â€“ including all randomized and treated patients who had a baseline HbA1c value. Treatment assignment as randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral Placebo</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg orally once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="155"/>
            <count group_id="B4" value="494"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="9.4"/>
                    <measurement group_id="B2" value="58.6" spread="9.8"/>
                    <measurement group_id="B3" value="59.9" spread="10.5"/>
                    <measurement group_id="B4" value="58.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment</title>
        <description>Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment</description>
        <time_frame>Baseline and 18 weeks</time_frame>
        <population>FAS18-completers-included FAS patients not prematurely discontinue prior to Week 18, completed required minimum treatment duration, and had an on treatment HbA1c value within Week 18 time window. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF-18) was used for imputation.
(LOCF-18)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment</title>
          <description>Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment</description>
          <population>FAS18-completers-included FAS patients not prematurely discontinue prior to Week 18, completed required minimum treatment duration, and had an on treatment HbA1c value within Week 18 time window. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF-18) was used for imputation.
(LOCF-18)</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.07"/>
                    <measurement group_id="O2" value="-0.58" spread="0.07"/>
                    <measurement group_id="O3" value="-0.75" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null and alternative hypotheses to be tested:
H0,1: No difference in change from baseline to Week 18 in HbA1c between empagliflozin 10 mg and placebo
H1,1: A difference in change from baseline to Week 18 in HbA1c between empagliflozin 10 mg and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hypotheses were tested at significance level of 0.025, which is half of overall alpha of 0.05, split equally between 2 treatment comparisons. This maintained the overall type-I (alpha) at 5%. There was no a priori assumption on testing order.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA that included treatment group and geographic region as fixed effects along with baseline HbA1c as covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
            <estimate_desc>The primary analysis consisted of the pair-wise comparisons between each dose of empagliflozin versus placebo using the adjusted means from the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null and alternative hypotheses to be tested:
H0,2: No difference in change from baseline to Week 18 in HbA1c between empagliflozin 25 mg and placebo
H1,2: A difference in change from baseline to Week 18 in HbA1c between empagliflozin 25 mg and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hypotheses were tested at significance level of 0.025, which is half of overall alpha of 0.05, split equally between 2 treatment comparisons. This maintained the overall type-I (alpha) at 5%. There was no a priori assumption on testing order.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA that included treatment group and geographic region as fixed effects along with baseline HbA1c as covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.47</ci_upper_limit>
            <estimate_desc>The primary analysis consisted of the pair-wise comparisons between each dose of empagliflozin versus placebo using the adjusted means from the model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment</title>
        <description>Patients that had a reduction in HbA1c of at least 0.5% from baseline to 18, 54 and 78 weeks of treatment</description>
        <time_frame>Baseline and 18, 54 and 78 weeks</time_frame>
        <population>FAS with non-completers considered failure (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment</title>
          <description>Patients that had a reduction in HbA1c of at least 0.5% from baseline to 18, 54 and 78 weeks of treatment</description>
          <population>FAS with non-completers considered failure (NCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>78 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.518</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.262</ci_lower_limit>
            <ci_upper_limit>9.334</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.883</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.859</ci_lower_limit>
            <ci_upper_limit>8.338</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.471</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.077</ci_lower_limit>
            <ci_upper_limit>5.802</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.825</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.268</ci_lower_limit>
            <ci_upper_limit>6.451</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 78 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.802</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.639</ci_lower_limit>
            <ci_upper_limit>4.789</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 78 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.527</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.051</ci_lower_limit>
            <ci_upper_limit>6.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</title>
        <description>Change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
        <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
        <population>FAS observed cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</title>
          <description>Change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
          <population>FAS observed cases (OC)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 18 Change from BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" spread="5.48"/>
                    <measurement group_id="O2" value="-14.79" spread="3.93"/>
                    <measurement group_id="O3" value="-27.03" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 54 Change from BL (N=103,111,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="5.08"/>
                    <measurement group_id="O2" value="-9.59" spread="4.69"/>
                    <measurement group_id="O3" value="-23.75" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 78 Change from BL (N=92,104,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.53" spread="4.95"/>
                    <measurement group_id="O2" value="-7.75" spread="4.66"/>
                    <measurement group_id="O3" value="-21.62" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-28.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.54</ci_lower_limit>
            <ci_upper_limit>-19.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 25 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-34.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.67</ci_lower_limit>
            <ci_upper_limit>-24.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 10 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0328</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-10.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.62</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-19.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.31</ci_lower_limit>
            <ci_upper_limit>-9.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3216</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.01</ci_lower_limit>
            <ci_upper_limit>4.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0229</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-11.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.24</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</title>
        <description>Percent change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
        <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
        <population>FAS (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment</title>
          <description>Percent change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment</description>
          <population>FAS (OC)</population>
          <units>percentage of Change from BL in FPG</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 18 % CHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.02" spread="6.32"/>
                    <measurement group_id="O2" value="-2.80" spread="3.17"/>
                    <measurement group_id="O3" value="-13.43" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 54 % CHG (N=103,111,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="5.58"/>
                    <measurement group_id="O2" value="0.67" spread="4.05"/>
                    <measurement group_id="O3" value="-11.59" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 78 % CHG (N=92,104,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="5.67"/>
                    <measurement group_id="O2" value="2.43" spread="4.18"/>
                    <measurement group_id="O3" value="-9.52" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-25.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.38</ci_lower_limit>
            <ci_upper_limit>-14.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.62</ci_lower_limit>
            <ci_upper_limit>-20.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0484</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-10.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.33</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-19.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.84</ci_lower_limit>
            <ci_upper_limit>-8.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3517</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.71</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline FPG, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-12.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.69</ci_lower_limit>
            <ci_upper_limit>-2.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment</title>
        <description>Change from baseline in basal insulin dose/day after 54 and 78 weeks of treatment</description>
        <time_frame>Baseline, 54 and 78 weeks</time_frame>
        <population>FAS (OC-78) for week 54 FAS78-completers (LOCF-78) for week 78 - Values after start of antidiabetic rescue therapy except changes in basal insulin dose were set to missing and last observation carried forward (LOCF) was used for imputation of missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment</title>
          <description>Change from baseline in basal insulin dose/day after 54 and 78 weeks of treatment</description>
          <population>FAS (OC-78) for week 54 FAS78-completers (LOCF-78) for week 78 - Values after start of antidiabetic rescue therapy except changes in basal insulin dose were set to missing and last observation carried forward (LOCF) was used for imputation of missing values</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 54 (N=112,122,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" spread="1.60"/>
                    <measurement group_id="O2" value="-1.20" spread="1.40"/>
                    <measurement group_id="O3" value="-1.12" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="2.06"/>
                    <measurement group_id="O2" value="-0.70" spread="1.85"/>
                    <measurement group_id="O3" value="-0.39" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin versus Placebo 10 mg at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0213</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.32</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
            <estimate_desc>Week 54 model includes, baseline basal insulin, baseline HbA1c as linear covariate(s), geographical region, treatment, visit and visit by treatment interaction as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin versus Placebo 25 mg at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0237</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.62</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
            <estimate_desc>Week 54 model includes, baseline basal insulin, baseline HbA1c as linear covariate(s), geographical region, treatment, visit and visit by treatment interaction as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin versus Placebo 10 mg at 78 weeks
H0,1a: No difference in change from baseline to Week 78 in basal insulin dose between Empagliflozin 10 mg and placebo H1,1a: A difference in change from baseline to Week 78 in basal insulin dose between Empagliflozin 10 mg and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <p_value_desc>Hierarchical testing approach was applied to Empagliflozin 10 mg vs Placebo. If null hypothesis is rejected for the primary endpoint, at 0.025 (2-sided), testing of the key secondary endpoints continued in a hierarchical fashion for the same dose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model for Week 78 includes baseline basal insulin, baseline HbA1c as linear covariate(s) and geographical region, treatment as fixed effect(s)</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-6.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.18</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.56</ci_lower_limit>
            <ci_upper_limit>-1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin versus Placebo 25 mg at 78 weeks
H0,1a: No difference in change from baseline to Week 78 in basal insulin dose between Empagliflozin 25 mg and placebo H1,1a: A difference in change from baseline to Week 78 in basal insulin dose between Empagliflozin 25 mg and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0090</p_value>
            <p_value_desc>Hierarchical testing approach was applied to Empagliflozin 25 mg vs Placebo. If null hypothesis is rejected for the primary endpoint, at 0.025 (2-sided), testing of the key secondary endpoints continued in a hierarchical fashion for the same dose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model for Week 78 includes baseline basal insulin, baseline HbA1c as linear covariate(s) and geographical region, treatment as fixed effect(s)</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.00</ci_lower_limit>
            <ci_upper_limit>-0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment</title>
        <description>Change from baseline in body weight after 18, 54 and 78 weeks of treatment</description>
        <time_frame>Baseline, 18, 54, 78 weeks</time_frame>
        <population>FAS (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment</title>
          <description>Change from baseline in body weight after 18, 54 and 78 weeks of treatment</description>
          <population>FAS (OC)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.21"/>
                    <measurement group_id="O2" value="-2.06" spread="0.22"/>
                    <measurement group_id="O3" value="-0.91" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 weeks (N=114,120,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.32"/>
                    <measurement group_id="O2" value="-2.28" spread="0.33"/>
                    <measurement group_id="O3" value="-2.23" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>78 weeks (N=100,113,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.28"/>
                    <measurement group_id="O2" value="-2.61" spread="0.31"/>
                    <measurement group_id="O3" value="-1.99" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 18 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3818</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>-1.22</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.81</ci_lower_limit>
            <ci_upper_limit>-1.45</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes, baseline weight, baseline HbA1c as covariates, geographic region, treatment, visit and visit by treatment interaction as fixed effects</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.39</ci_lower_limit>
            <ci_upper_limit>-0.85</ci_upper_limit>
            <estimate_desc>Model includes baseline weight, baseline HbA1c as linear covariates, geographical region, treatment, visit and visit by treatment interaction as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Follow-up</title>
        <description>Change from baseline in body weight at follow up (82 weeks)</description>
        <time_frame>Baseline and 82 weeks</time_frame>
        <population>FAS-FU (OR)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Follow-up</title>
          <description>Change from baseline in body weight at follow up (82 weeks)</description>
          <population>FAS-FU (OR)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.56" spread="25.87"/>
                    <measurement group_id="O2" value="90.44" spread="19.35"/>
                    <measurement group_id="O3" value="93.98" spread="20.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="12.20"/>
                    <measurement group_id="O2" value="-2.02" spread="4.04"/>
                    <measurement group_id="O3" value="-1.05" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from last value on treatment N=111,118,109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="16.84"/>
                    <measurement group_id="O2" value="0.62" spread="2.11"/>
                    <measurement group_id="O3" value="1.34" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c after 54 and 78 weeks of treatment</description>
        <time_frame>Baseline, 54 and 78 weeks</time_frame>
        <population>Week 54 - FAS (OC-78) Week 78 - FAS78-completers (LOCF-78)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c after 54 and 78 weeks of treatment</description>
          <population>Week 54 - FAS (OC-78) Week 78 - FAS78-completers (LOCF-78)</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 54 (N=113,121,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.08"/>
                    <measurement group_id="O2" value="-0.59" spread="0.08"/>
                    <measurement group_id="O3" value="-0.84" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (N=112,127,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.10"/>
                    <measurement group_id="O2" value="-0.51" spread="0.09"/>
                    <measurement group_id="O3" value="-0.68" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 10 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
            <estimate_desc>Model includes baseline HbA1c as linear covariate(s), geographical region, treatment, visit and visit by treatment interaction as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 54 - Empagliflozin 25 mg vs Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
            <estimate_desc>Model includes baseline HbA1c as linear covariate(s), geographical region, treatment, visit and visit by treatment interaction as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 10 mg vs Placebo
H0,1b: The change from baseline to Week 78 in HbA1c between empagliflozin 10 mg and placebo â‰¥0.3% H1,1b: The change from baseline to Week 78 in HbA1c between empagliflozin 10 mg and placebo &lt;0.3%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For non-inferiority, a one-sided test at the significance level of 0.0125 was performed using a chosen margin of 0.3% difference between each dose of empagliflozin and placebo.
If the non-inferiority of empagliflozin to placebo with respect to change from baseline in HbA1c after 78 weeks of treatment could be concluded for a specific dose, subsequent testing of superiority was performed at the significance level of 0.025 for the relevant empagliflozin dose versus placebo comparison.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <p_value_desc>Hierarchical testing approach was applied to Empagliflozin 10 mg vs Placebo. If null hypothesis is rejected for the primary endpoint, at 0.025 (2-sided), testing of the key secondary endpoints continued in a hierarchical fashion for the same dose.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
            <estimate_desc>Model includes baseline HbA1c as linear covariate(s), geographical region, treatment as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from BL at week 78 - Empagliflozin 25 mg vs Placebo
H0,1b: The change from baseline to Week 78 in HbA1c between empagliflozin 25 mg and placebo â‰¥0.3% H1,1b: The change from baseline to Week 78 in HbA1c between empagliflozin 25 mg and placebo &lt;0.3%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For non-inferiority, a one-sided test at the significance level of 0.0125 was performed using a chosen margin of 0.3% difference between each dose of empagliflozin and placebo.
If the non-inferiority of empagliflozin to placebo with respect to change from baseline in HbA1c after 78 weeks of treatment could be concluded for a specific dose, subsequent testing of superiority was performed at the significance level of 0.025 for the relevant empagliflozin dose versus placebo comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing approach was applied to Empagliflozin 25 mg vs Placebo. If null hypothesis is rejected for the primary endpoint, at 0.025 (2-sided), testing of the key secondary endpoints continued in a hierarchical fashion for the same dose.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
            <estimate_desc>Model includes baseline HbA1c as linear covariate(s), geographical region, treatment as fixed effect(s).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycemic Events</title>
        <description>Confirmed hypoglycemic events refer to all hypoglycemic events that had a glucose value â‰¤70 ml/dL or where assistance was required. Symptomatic hypoglycemic events were to be reported as adverse events. Investigator-defined hypoglycaemia adverse events include all events that investigator marked as â€˜Hypoglycaemic eventâ€™ in CRFs, regardless of the reported term or blood glucose value. It may include hypoglycemia itself as reported term or any other symptoms that that investigator may have attributed to hypoglycemia (e.g. dizziness, hyperhidrosis, and asthenia).</description>
        <time_frame>During the course of the study (82 weeks)</time_frame>
        <population>Treated set (TS). Treatment assignment as first medication taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycemic Events</title>
          <description>Confirmed hypoglycemic events refer to all hypoglycemic events that had a glucose value â‰¤70 ml/dL or where assistance was required. Symptomatic hypoglycemic events were to be reported as adverse events. Investigator-defined hypoglycaemia adverse events include all events that investigator marked as â€˜Hypoglycaemic eventâ€™ in CRFs, regardless of the reported term or blood glucose value. It may include hypoglycemia itself as reported term or any other symptoms that that investigator may have attributed to hypoglycemia (e.g. dizziness, hyperhidrosis, and asthenia).</description>
          <population>Treated set (TS). Treatment assignment as first medication taken.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of &lt;7.0% After 18, 54, and 78 Weeks of Treatment</title>
        <description>The occurrence of treat to target efficacy response, that is an HbA1c under treatment of &lt;7.0% After 18, 54, and 78 weeks of treatment</description>
        <time_frame>Baseline, 18, 54 and 78 weeks</time_frame>
        <population>FAS (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral Placebo</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of &lt;7.0% After 18, 54, and 78 Weeks of Treatment</title>
          <description>The occurrence of treat to target efficacy response, that is an HbA1c under treatment of &lt;7.0% After 18, 54, and 78 weeks of treatment</description>
          <population>FAS (NCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>78 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.846</ci_lower_limit>
            <ci_upper_limit>9.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 18 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.636</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.083</ci_lower_limit>
            <ci_upper_limit>10.321</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1248</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.750</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.856</ci_lower_limit>
            <ci_upper_limit>3.575</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 54 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0132</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.423</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.203</ci_lower_limit>
            <ci_upper_limit>4.879</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 10 mg vs Placebo at 78 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0986</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.939</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.884</ci_lower_limit>
            <ci_upper_limit>4.256</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Empagliflozin 25 mg vs Placebo at 78 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression includes treatment, geographical region and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.239</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.518</ci_lower_limit>
            <ci_upper_limit>6.911</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the course of the study (82 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral Placebo</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg orally once daily</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-Chiari malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Accident at home</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malignant fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

